Fibromyalgia, milnacipran and experimental pain modulation: study protocol for a double blind randomized controlled trial

Nicolas Macian, Bruno Pereira, Coralie Shinjo, Claude Dubray, Gisèle Pickering, Nicolas Macian, Bruno Pereira, Coralie Shinjo, Claude Dubray, Gisèle Pickering

Abstract

Background: The prevalence of fibromyalgia increases worldwide and is characterized by widespread and chronic pain. Treatment is difficult and includes both drug and non-drug approaches. Milnacipran, an antidepressant, is used for fibromyalgia, with a possible beneficial effect on central pain modulation. Our hypothesis is that the efficacy of milnacipran in fibromyalgia depends on the performance of pain inhibitory controls.

Methods/design: A randomized, double blind, clinical trial (NCT01747044) with two parallel groups, in 48 women with fibromyalgia, is planned in the Clinical Pharmacology Center, University Hospital, Clermont-Ferrand, France. Conditioned pain modulation (estimated with thermal stimuli using a numeric pain rating scale), the primary endpoint measure, is evaluated before and one month after treatment with milnacipran or placebo. Secondary outcome measures include the predictability of pain descending pathways performance for milnacipran efficacy, tolerance and cognitive function. Data analysis is performed using mixed models; the tests are two-sided, with a type I error set at alpha = 0.05. Not only will this trial allow estimation of the beneficial effect of milnacipran on pain and on descending pain pathways but it will also evaluate whether the performance of this modulatory system could be predictive of its efficacy in alleviating pain.

Discussion: This method would allow clinicians to take a pro-active attitude by performing a rapid psychophysical test before starting milnacipran treatment and would avoid unnecessary prescription while preventing therapeutic failure in patients who often face this recurrent problem.

Trial registration: ClinicalTrials.gov NCT01747044 .

References

    1. Bannwarth B, Blotman F, Roué-Le Lay K, Caubère J-P, André E, Taïeb C. Fibromyalgia syndrome in the general population of France: a prevalence study. Joint Bone Spine. 2009;76:184–7. doi: 10.1016/j.jbspin.2008.06.002.
    1. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005;75:6–21.
    1. Branco JC, Cherin P, Montagne A, Bouroubi A. Multinational coordinator study group. Longterm therapeutic response to milnacipran treatment for fibromyalgia: a European 1-year extension study following a 3-month study. J Rheumatol. 2011;38:1403–12. doi: 10.3899/jrheum.101025.
    1. Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600–10. doi: 10.1002/acr.20140.
    1. Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain. 1997;70:41–51. doi: 10.1016/S0304-3959(96)03295-2.
    1. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain. 1997;13:189–96. doi: 10.1097/00002508-199709000-00003.
    1. Sigurdsson A, Maixner W. Effects of experimental and clinical noxious counterirritants on pain perception. Pain. 1994;57:265–75. doi: 10.1016/0304-3959(94)90002-7.
    1. Edwards RR, Ness TJ, Weigent DA, Fillingim RB. Individual differences in diffuse noxious inhibitory controls (DNIC): association with clinical variables. Pain. 2003;106:427–37. doi: 10.1016/j.pain.2003.09.005.
    1. Staud R, Robinson ME, Vierck CJ, Jr, Price DD. Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. Pain. 2003;101:167–74. doi: 10.1016/S0304-3959(02)00325-1.
    1. Van Wijk G, Veldhuijzen DS. Perspective on diffuse noxious inhibitory controls as a model of endogenous pain modulation in clinical pain syndromes. J Pain. 2010;11:408–19. doi: 10.1016/j.jpain.2009.10.009.
    1. Pickering G, Pereira B, Dufour E, Soule S, Dubray C. Impaired modulation of pain in patients with postherpetic neuralgia. Pain Res Manag. 2014;19:e19–23.
    1. Yarnitsky D, Arendt-Nielsen L, Bouhassira D, Edwards RR, Fillingim RB, Granot M, et al. Recommendations on terminology and practice of psychophysical DNIC testing. Eur J Pain. 2010;14:339. doi: 10.1016/j.ejpain.2010.02.004.
    1. Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain. 2012;153:1193–8. doi: 10.1016/j.pain.2012.02.021.
    1. Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536–41. doi: 10.1136/ard.2007.071522.
    1. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136:432–44. doi: 10.1016/j.pain.2008.02.024.
    1. Ormseth MJ, Eyler AE, Hammonds CL, Boomershine CS. Milnacipran for the management of fibromyalgia syndrome. J Pain Res. 2010;3:15–24.
    1. Palmer RH, Periclou A, Banerjee P. Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia. Ther Adv Musculoskelet Dis. 2010;2:201–20. doi: 10.1177/1759720X10372551.
    1. Arnold LM, Palmer RH, Ma Y. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clin J Pain. 2013;29:1021–8. doi: 10.1097/AJP.0b013e31828440ab.
    1. Pickering G, Pereira B, Clère F, Sorel M, de Montgazon G, Navez M, et al. Cognitive function in older patients with postherpetic neuralgia. Pain Pract Off J World Inst Pain. 2014;14:E1–7. doi: 10.1111/papr.12079.
    1. Efird J. Blocked randomization with randomly selected block sizes. Int J Environ Res Public Health. 2011;8(1):15–20. doi: 10.3390/ijerph8010015.
    1. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain. 2005;114(1–2):295–302. doi: 10.1016/j.pain.2004.12.032.
    1. Granovsky Y, Matre D, Sokolik A, Lorenz J, Casey KL. Thermoreceptive innervation of human glabrous and hairy skin: a contact heat evoked potential analysis. Pain. 2005;115:238–47. doi: 10.1016/j.pain.2005.02.017.
    1. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ. 2001;323(7321):1123–4. doi: 10.1136/bmj.323.7321.1123.
    1. Denk F, McMahon SB, Tracey I. Pain vulnerability: a neurobiological perspective. Nat Neurosci. 2014;17:192–200. doi: 10.1038/nn.3628.
    1. Gendreau J, Palmer R, Thacker K. (170) Milnacipran is safe and well tolerated in the treatment of fibromyalgia syndrome. J Pain. 2008;9(4, suppl, 2):18–8. doi: 10.1016/j.jpain.2008.01.090.
    1. Yarnitsky D, Crispel Y, Eisenberg E, Granovsky Y, Ben-Nun A, Sprecher E, et al. Prediction of chronic post-operative pain: pre-operative DNIC testing identifies patients at risk. Pain. 2008;138:22–8. doi: 10.1016/j.pain.2007.10.033.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere